In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure

在 1a 期渐进式临床试验中，自体间充质干细胞输注治疗肾血管疾病可增加血流量和肾小球滤过率，同时降低炎症生物标志物和血压